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Background: To determine the relationship between renal cell carcinoma subtypes and the associated mortality and
biochemical parameters. An additional aim was to analyze multiphasic multidetector computed tomography findings.
Methods: This study is a hospital-based retrospective investigation, using 211 patients with a diagnosis of renal cell
carcinoma upon computed tomography examination. The histological subtypes included clear cell in 119 patients,
chromophobe cell in 30 patients, papillary cell in 25 patients, mixed cell in 32 patients, and sarcomatoid cell in
4 patients.
Results: The mean age of the patients participating in this study was 61.18 ± 11.81 years, and the mortality rate was
10.4% (n = 22) through the 2-year follow-up. The ratios of both the neutrophil-to-lymphocyte upon admission to the
hospital and platelet-to-lymphocyte of the non-surviving group were significantly higher than those of the surviving
group (p < 0.05). When the analysis of the 2-year survival of the patients was examined according to the median
platelet-to-lymphocyte ratio values, the Kaplan-Meier survival curves were significantly different between the surviving
and non-surviving groups (p = 0.01). In two-way analysis of variance test, statistically significant results which were
influenced by mortality (p = 0.028) and were found between renal cell carcinoma subtypes in the computed tomography
density of corticomedullary phase (p = 0.001).
Conclusions: The neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio may represent widely available
biomarkers in renal cell carcinoma, and the logistic regression model indicated that neutrophil-to-lymphocyte
ratio was a significant predictor for mortality. According to the median platelet-to-lymphocyte ratio values, the
Kaplan-Meier survival curves were significantly different between the surviving and non-surviving groups.
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Renal cell carcinoma (RCC) is the most common pri-
mary renal tumor, and originates from the renal cortex
[1]. Worldwide, the incidence of RCC has increased over
the last thirty years [2]. After the surgical treatment of
RCC, the possibility of recurrent tumors is 10-20% [3-5]
therefore, with the recent peripheral blood sampling in
the diagnosis of RCC, the development of different prog-
nostic factors is necessary. For this purpose, some prog-
nostic markers and models have been developed; [6,7]
for example, changes like neutrophilia, lymphopenia, and
thrombocytosis in the peripheral blood are evaluated in
response to systemic inflammation. Prognostic factors,
such as the neutrophil-to-lymphocyte ratio (NLR) and
platelet-to-lymphocyte ratio (PLR), are used for an assess-
ment of the response to systemic inflammation and RCC
prognosis [8-11]. Various studies have shown that a high
NLR is associated with poor prognosis in RCC; however,
in most of these studies, clear cell, non-clear cell, meta-
static, and non-metastatic RCC groups were included
[11-14]. The relationship of the histological RCC subtypes
with the prognostic factors, such as NLR, PLR, or mortal-
ity, has not been actively discussed in the literature. In this
study, clear cell/non-clear cell or metastatic/non-meta-
static differentiation has been made. Also, multiphasic
multidetector computed tomography (CT) findings are in-
cluded, in addition to the hematological parameters. Most
commonly used imaging modality in the detection of renal
masses is multidetector CT. Many studies in the past re-
ported significant findings that revealed the different en-




This study is a hospital-based retrospective investigation,
where 231 patients with RCCs over the age of 18, who
were admitted to the Meram Medical School Hospital,
were screened between January of 2008 and March of
2013, were enrolled in the study after providing written in-
formed consent. Patients with a diagnosis of RCC upon
computed tomography (CT) examination were included
in the study. The RCCs were diagnosed by resection, and
20 patients without pathological correlation were excluded
from the study population. This retrospective study was
approved by the Necmettin Erbakan University, Meram
School of Medicine Hospital Institutional Review Board.
Study protocol
The RCC cases were screened from the database of the
hospital’s electronic record system. The demographic and
clinical characteristics of 211 patients who met the inclu-
sion criteria were obtained from the patient’s archived
records to evaluate mortality. RCCs were detected viamultiphasic multidetector CT, and hospital mortalities of
the patients were determined according to their medical
records. Fuhrman grade system was used for pathological
grading in RCC.
Blood sample analysis
A complete blood count analysis was performed using the
peripheral venous blood samples taken upon admission to
the urology department of the hospital. The blood samples
were collected in a calcium EDTA (Ethylenediaminetetra-
acetic acid) tube, and blood counts have been evaluated
using an auto-analyzer (Abbott Cell-Dyn Ruby Hematology
Analyzer, Illinois, USA) in our hospital since 2007. The
NLR was calculated as the ratio of neutrophils to lympho-
cytes, and the PLR was calculated as the ratio of platelets to
lymphocytes in the peripheral blood. In addition, other rou-
tine laboratory findings were examined using the digital
record systems of the hospital.
Equipment and scanning
One radiologist (SK), with 9 years of experience in CT, car-
ried out the multiphasic multidetector CT examinations.
All of the patients were examined using a 64-multi-
detector CT (64-MDCT) scanner (Siemens SOMATOM
Sensation 64, Erlangen, Germany) with the following scan-
ning parameters: 0.6 mm collimation, 1.5 mm slice thick-
ness, 1.4 mm increment, 100 kV and 135 mAs, a pitch of
0.9, and a gantry rotation time of 0.33 s. A scout image was
acquired while the patient was in the supine position, and
the area from the diaphragm to the end of the iliac bones
was identified as the field of examination. All patients re-
ceived 100 ml of nonionic contrast medium (Ultravist 300;
Bayer Schering Pharma, Berlin, Germany), which was man-
aged through a catheter in the right antecubital vein. The
contrast was executed at a flow rate of 5 mm/sec using an
automated injector, and the scan was executed 20 s after
the start of the injection. Firstly, unenhanced phase was ob-
tained. After the nonionic contrast medium was given, the
corticomedullary phase in the 25th second, nephrographic
phase in the 60th second, and excretory phase in the 5th mi-
nute were obtained. Lesion sizes were measured in the
nephrographic phase and densities were measured in the
unenhanced, corticomedullary, nephrographic and excre-
tory phases. Density measurements were made from the 3
separate 10 mm2 solid circular region of interest (ROI) field
in the mass and then the average of these values were cal-
culated for the mass attenuation. The most homogeneous
and dense contrast enhanced areas were used to obtain the
attenuation values. In contrast, we avoided from necrotic,
cystic and calcified areas to measure the density.
Statistical analysis
Statistical analyses were performed using SPSS version
20.0 software (SPSS, Chicago, IL, USA), and the data
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dian (interquartile range [IQR]). Subsequently, the lesion
sizes were categorized as less than 40 mm, 41–80 mm,
81–120 mm, 121–160 mm, and 161–200 mm. Distribution
normality was analyzed with the Kolmogorov-Smirnov test,
and the differences between the two groups were tested
using the independent Student’s t-test for normally distrib-
uted variables, while the Mann–Whitney U test was used
for a comparison of the non-parametrically distributed vari-
ables. The differences between the categorical variables
were determined by using the χ2-test. While investigating
the associations between non-normally distributed and/or
ordinal variables, the correlation coefficients and their sig-
nificance were calculated using the Spearman test. One-
way analysis of variance was used to compare CT density
among the subtypes of RCCs. Levene’s test was used to as-
sess the homogeneity of the variances. When an overall
significance was observed, pair wise post-hoc tests were
performed using Tamhane’s T2 test. When investigating
the changes in lesion density of corticomedullary phase by
RCC’s subtypes, the effects of mortality was adjusted using
two-way analysis of variance test respectively. Kruskal-
Wallis tests were conducted to compare the differences in
CT density and NLR among the pathological subtypes,
and hemoglobin and creatinine among lesion sizes and
tumor stage. The Mann–Whitney U test was performed
to test the significance of the pair-wise differences using
the Bonferroni correction to adjust for multiple compari-
sons. Two-tailed P values of less than 0.05 were accepted
to be statistically significant. The logistic regression ana-
lysis was performed to determine the predictors of 2-year
mortality. The hematological parameters, age, gender,
NLR, and PLR were included in this regression model
as independent variables. The best cut-off value of the
hematological parameters was estimated using regression
tree analysis.
Results
The mean age of the 211 patients who were diagnosed
with renal cell cancer was 61.18 ± 11.81 years, and the
mortality rate was 10.4% (n = 22) by the 2-year follow-
up. The histological subtype was clear cell carcinoma in
119 patients, chromophobe cell carcinoma in 30 patients,
papillary cell carcinoma in 25 patients, mixed cell carcin-
oma in 32 patients, and sarcomatoid cell carcinoma in 4
patients. The mean and 95% CI of CT density were dem-
onstrated in subtypes of RCCs (Table 1). Demographic
and laboratory findings of the surviving and non-surviving
patients are reported in Table 2. Both the NLR upon ad-
mission to the hospital and the PLR of the non-surviving
group were significantly higher than those of the surviving
group (p < 0.05). Also, there were significant differences in
age, lesion size, WBCs, neutrophils, lymphocytes, platelets,
hemoglobin, creatinine, metastasis, and tumor stage (Table 2).Age, NLR, hemoglobin, and creatinine were independent
predictors of mortality in the logistic regression analysis
(Table 3). The optimal cut-off value for NLR as a predictor
of mortality was determined to be 2.7 in the ROC curve
analysis. On this level, the sensitivity was 81.8%, specificity
was 59.3%, positive predictive value was 18.9%, and the
negative predictive value was 96.6% (Figure 1). There is no
significant difference in NLR between pathological sub-
types (p = 0.928). The optimal cut-off value for the PLR
was determined to be 151. When the analysis of the 2-year
survival of the patients was examined according to median
PLR values, the Kaplan-Meier survival curves were signifi-
cantly different between the surviving and non-surviving
groups (p = 0.01) (Figure 2). In the Mann–Whitney U test,
statistically significant results were found in the WBCs
(p = 0.021), platelets (p = 0.003), hemoglobin (p < 0.001),
lesion density of excretory phase (p = 0.048) and creatinine
(p < 0.001) between the male and female patients; the PLR
(p = 0.04) and lesion density of corticomedullary phase
(p = 0.001) between the clear cell and non-clear cell le-
sions; and the lesion size (p < 0.001), creatinine (p < 0.001),
and hemoglobin (p = 0.001) between metastasis and non-
metastasis. When the males and females were compared,
there was a statistically significant difference in the metas-
tasis between the two groups (p = 0.02). In the Kruskal-
Wallis test, there was a statistically significant difference in
corticomedullary phase’s density between the clear cell
and papillary (p < 0.001), chromophobe and papillary (p =
0.016), and papillary and mixed (p = 0.002) RCCs. In the
Kruskal-Wallis test, there was a statistically significant dif-
ference in hemoglobin and creatinine between stage 1 and
4 (p < 0.001). In the independent Student’s t-test, the le-
sion’s density in corticomedullary phase was found 21,12
HU higher than men in women (p = 0.034 CI%95 1,59-
40,65), the lesion’s density in corticomedullary phase was
found 27,34 HU higher than non-clear cell RCCs in clear
cell RCCs (p = 0.006) (CI%95 8,16-46,53), the lesion’s
density in nephrographic phase was found 19,73 HU higher
than non-clear cell RCCs in clear cell RCCs (p < 0.001)
(CI%95 9,04-30,42) and the lesion’s density in corticome-
dullary phase was found 29,53 HU higher than non-
surviving in surviving group (p = 0.048) (CI%95 0,23-58,47).
In the One-way analysis of variance test, statistically signifi-
cant results were found between clear cell and papillary
(p < 0.001), clear cell and sarcomatoid (p < 0.001), papillary
and mix (p = 0.046), papillary and sarcomatoid subtypes
(p < 0.031) in the lesion density of early arterial phase.
Statistically significant results were found between clear
cell and papillary (p = 0.001), papillary and mix (p = 0.039)
in the lesion density of nephrographic phase. In Spear-
man test, positive medium correlation (r 0.40-0.60) was
found between unenhanced and corticomedullary phases.
Positive good correlation (r 0.60-0.70) was found between
unenhanced and corticomedullary phases. Positive good
Table 1 The mean and 95% CI of CT density in subtypes of RCCs
Clear cell RCC Chromophobe RCC Papillary RCC Mixed RCC Sarcomatoid RCC
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
unenhanced 31,43 ± 1,50 28,41-34,45 38,25 ± 5,35 25,60-50,90 31,70 ± 3,81 23,08-40,32 33,78 ± 3,42 25,90-41,65 29,50 ± 1,50 10,44-48,56
corticomedullary 118,24 ± 5,83 106,47-130,01 117,38 ± 18,21 74,33-160,42 58,20 ± 5,21 46,41-69,99 106,33 ± 12,49 77,52-135,15 79,00 ± 1,00 66,29-91,71
nephrographic 92,83 ± 2,78 87,23-98,44 88,13 ± 12,54 58,47-117,78 55,10 ± 6,24 40,99-69,21 82,56 ± 5,38 70,15-94,96 60,50 ± 9,50 60,21-181,21
excretory 66,62 ± 2,42 61,74-71,50 63,00 ± 9,45 40,66-85,34 51,70 ± 7,23 35,33-68,07 66,56 ± 5,62 53,61-79,50 47,50 ± 4,50 9,68-104,68


















Table 2 Demographics and laboratory findings of survived and non-survived patients
Survived (n = 189)
mean ± SD/median (IQR)
Non-survived (n = 22)
mean ± SD/median (IQR)
P Z
Age years 58.1 ± 13.5 67.9 ± 12.5 0.005
Gender (F/M) 69/120 7/15 0.665
Lesion size 56.9 ± 30.6 75.2 ± 35.2 0.004 −2.853
WBC (10^3/uL) 7.89 (7.63) 11.96 (10.30) 0.002 −3.075
Neutrophil (10^3/uL) 5.09 (4.92) 8.50 (7.71) 0.002 −3.033
Lymphocyte(10^3/uL) 2.13 (2.01) 2.08 (2.10) 0.457 −0.744
NLR 2.60 (2.24) 4.28 (3.75) <0.001 −3.733
Platelet (10^3/uL) 259.0 ± 73.1 306.1 ± 65.9 0.028 −2.203
PLR 134.2 (124.0) 150.2 (145.0) 0.038 −2.079
Hemoglobin mg/dl 13.0 ± 1.8 12.4 ± 1.6 0.001 −3.371
MPV 7.24 (7.20) 7.13 (7.86) 0.430 −0.790
Creatinine mg/dl 0.9 ± 0.3 1.2 ± 0.8 0.046 −1.996
CT density (HU)
Unenhanced 32.9 ± 1.4 29.7 ± 3.1 0.401
Corticomedullary 110.8 ± 5.3 81.4 ± 10.1 0.048
Nephrographic 86.5 ± 3.1 73 ± 5.3 0.118
Excretory 64.2 ± 2.5 59 ± 4.4 0.522 −0.640
Metastasis 44 12 0.002 9.88 chi-square
Pathologies Clearcell/Nonclear cell 103/86 16/6 0.103
Chromophobe/ Papillary/Mix/Sarcomatoid 29/25/29/2 1/0/3/2 0.692
Tumor Stage 1/2/3/4 105/27/13/44 7/1/2/12 0.005 −2.788
IQR: interquartile range, WBC: White blood cell count, NLR: Neutrophil-lymphocyte ratio, PLR: Platelet-lymphocyte ratio, MPV: Mid-platelet volume, CT: Computed
tomography, HU: Hounsfeld unit.
Keskin et al. BMC Urology 2014, 14:95 Page 5 of 8
http://www.biomedcentral.com/1471-2490/14/95correlation (r 0.60-0.70) was found between corticome-
dullary and nephrographic phases. Positive excellent
correlation (r 0.75-1.00) was found between nephro-
graphic and excretory phases (p < 0.05). In two-way ana-
lysis of variance test, statistically significant results
which were influenced by mortality (p = 0.028) and were
found between RCCs subtypes in the CT density of cor-
ticomedullary phase (p = 0.001).Table 3 Logistic regression results for the predictors of
mortality
Variables Odds ratio 95.0% CI HR P
The first step
Age 1.05 1.01-1.10 0.015
Gender 0.96 0.35-2.59 0.93
NLR 3.21 1.26-8.16 0.014
PLR 1.79 0.60-5.30 0.29
Hemoglobin 5.33 1.56-18.23 0.008
Creatinine 3.34 1.12-9.99 0.031
NLR: neutrophil/lymphocyte ratio, PLR: platelet/ lymphocyte ratio.Discussion
The aim of this study was to determine the relationship
between RCC subtypes and the associated mortality
and biochemical parameters. An additional aim was to
analyze the multiphasic multidetector CT findings. Pre-
vious studies have revealed that inflammatory markers
are associated with RCC prognosis [18]. The NLR is a
systemic inflammation marker with a wide range of use,
low cost, and easy accessibility [19-21], and previous
studies have concluded that the NLR is a predictor of
mortality in RCC patients [22,23]. As far as we know, in-
flammatory markers, such as the NLR and PLR, have
been studied in RCC patients after they were classified
generally as metastatic or not. However, these studies were
focused on clear cell and metastatic RCCs. Additionally, in
our study, the relationships between the RCC histological
subtypes and mortality, systemic markers, and multiphasic
multidetector CT findings were investigated. Our results
suggest that in patients with RCC, there is a statistically
significant difference in the NLR between survivors and
non-survivors.
The logistic regression model indicated that the NLR
was a significant predictor for mortality. Similar to our
Figure 1 ROC curve showed predictive value of NLR for death.
Figure 2 Kaplan Meier survive curve according to the PLR median value.
Keskin et al. BMC Urology 2014, 14:95 Page 6 of 8
http://www.biomedcentral.com/1471-2490/14/95
Keskin et al. BMC Urology 2014, 14:95 Page 7 of 8
http://www.biomedcentral.com/1471-2490/14/95findings, Ohno et al. concluded that high preoperative
NLR values are a predictor indicating mortality in RCC
[13]. However, unlike us, Jagdev et al. found that a high
NLR is not a predictor of prognosis in RCC [24]. Pichler
et al. inferred (different from us) that the preoperative
NLR is a predictor for mortality only in non-metastatic
clear cell RCC [25]. According to the median PLR
values, the Kaplan-Meier survival curves were signifi-
cantly different between the surviving and non-surviving
groups. The role of the histological subtype (papillary vs.
chromophobe) as an independent prognostic factor in
localized RCC, however, is still unclear.
In the literature, there were several studies including
patients with clear cell RCC and the subtypes [13,24-26].
However, there were no detected significant differences
in mortality between the histological subtypes in our
study. Dirican et al. [27] found no association between
age, platelet count, neutrophil count, PLR, and mortality
in metastatic RCC, except in lung metastasis. We found
a significant difference between age, platelet count, neu-
trophil count, PLR, and mortality in metastatic and non-
metastatic RCC.
In addition, we investigated the association between
multiphasic multidetector CT findings and the other pa-
rameters in RCC. It is noted that mortality increased
with an increased size of the lesion. Additionally, a sig-
nificant difference with reference to CT density was de-
termined in the evaluation of the lesion density between
RCCs subtypes in corticomedullary and nephrographic
phases. Similarly with Young et al. [28], significant differ-
ence between clear cell and papillary subtype in terms of
lesion density on corticomedullary and nephrographic
phase was detected. However, we didn’t identify differ-
ence on excretory phase. In our study, lesion density on
corticomedullary phase was siginificantly higher in the
dead patients compared with alive patients. Also, it is
understood that there is significant difference between
the RCC subtypes on corticomedullary phase and mor-
tality effect this. Unlike Young et al. siginificant differ-
ence was detected between clear cell and sarcomatoid;
papillary and mixed papillary; papillary and sarcomatoid
subtypes. Besides, Young et al. calculated the average of
two density values obtained from the two separate areas
of the lesion. However we have the average density
values of three different homogeneous enhanced areas.
Unlike Jung et al. [29], attenuation values obtained on
corticomedullary and nephrographic phases for clear cell
were significantly higher than the non-clear cell ones.
Again, different from Jung et al. our patient population
was higher and additionally mixed and sarcomatoid
types were included in our study. Also, differently, four
phased CT examination was obtained. Jung et al. didn’t
detect density differences in terms of gender. In our
study, there was significant difference detected betweenmale and female in terms of lesion density on the late
phase. Unlike Kim et al. [30] there was statistically signifi-
cant difference for lesion density on corticomedullary
phase between clear cell and papillary; clear cell and sarco-
matoid; papillary and mixed; papillary and sarcomatoid
subtypes. On nephrographic phase in terms of lesion
density, significant difference was detected between clear
cell and papillary; papillary and mixed subtypes.
Our study is retrospective so it has some limiting fac-
tors. The pathological evaluation was performed by two
different pathologists, and some prognostic factors, such
as tumor necrosis, was not taken into consideration. Fur-
thermore, the organs which the RCC metastasized to were
not classified in and of themselves. In the evaluation of
biochemical markers, only the preoperative period was
taken into consideration, but the postoperative values
were not included in the study. Clear cell RCC occurs
more often than the other subtypes, and studies in which
the clear cell and other subtypes are distributed homoge-
neously will provide more optimal results.
Conclusions
As a result of this study, the NLR and PLR were deter-
mined to be easily accessible markers in the prognosis of
RCC, and the usage of these markers may be helpful in
the management of high-risk RCC patients. In addition,
multidetector CT is useful to detect the differences in con-
trast enhancement patterns between the RCC subtypes.
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